Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialEugenio Mercuri, A. Nascimento, Wolfgang Müller‐Felber et al.|The Lancet Neurology|2024Cited by 128
Pamrevlumab, a Fully Human Monoclonal Antibody Targeting Connective Tissue Growth Factor, for Non-Ambulatory Patients with Duchenne Muscular DystrophyAnne M. Connolly, Ewa Carrier, Craig M. Zaidman et al.|Journal of Neuromuscular Diseases|2023Cited by 24
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O. Crawford, Barbara Steinborn, Eugenio Mercuri et al.|The Lancet Neurology|2025Cited by 22